Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat

@article{Egerton2008ModulationOS,
  title={Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat},
  author={Alice Egerton and Rabia Shabir Ahmad and Ella Hirani and Paul M. Grasby},
  journal={Psychopharmacology},
  year={2008},
  volume={200},
  pages={487-496}
}
RationaleAntagonism at serotonin 5-HT2A and 5-HT2C receptors modulates cortical and striatal dopamine (DA) release and may underlie some aspects of the clinical efficacy of ‘atypical’ antipsychotic compounds. However, it is not known whether 5-HT2A/2C receptor-mediated modulation of DA release can be quantified with non-invasive neurochemical imaging, as would be required for investigation of these processes in man.ObjectiveThe objective of the study was to perform a feasibility study in the… Expand
Serotonergic modulation of extrapyramidal motor disorders in mice and rats: Role of striatal 5-HT3 and 5-HT6 receptors
TLDR
It is suggested that serotonergic stimulation augments extrapyramidal motor disorders by activating the striatal 5- HT(3) and 5-HT(6) receptors and the antagonism of these receptors effectively alleviates antipsychotic-induced EPS. Expand
Effect of 5-HT2A receptor antagonism on levels of D2/3 receptor occupancy and adverse behavioral side-effects induced by haloperidol: a SPECT imaging study in the rat
TLDR
A partial contribution of a 5-HT 2A R antagonism to the efficacy and side-effect profile of antipsychotic agents is suggested. Expand
α2‐Adrenergic drugs modulate the binding of [18F]fallypride to dopamine D2/3 receptors in striatum of living mouse
TLDR
Findings are consistent with a tonic inhibition of dopamine release by α2 adrenergic receptors, such that α2 blockade increased the competition from endogenous dopamine at D2/3 receptors, thus reducing the [18F]fallypride BPND by about 20%. Expand
Striatal Dopamine Release and Genetic Variation of the Serotonin 2C Receptor in Humans
TLDR
Findings indicate that a putatively functional HTR2C variant (Ser23) is associated with greater striatal dopamine release during pain in healthy humans. Expand
Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain
Serotonin 2A (5-HT2A) receptors and dopamine D2 receptors are intimately related to the physiology and pathophysiology of neuropsychiatric disorders. A large number of studies have reported theExpand
Sensitivity of [11C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects
TLDR
Direct experimental support was gained for the suitability of [11C]ORM-13070 for imaging of brain noradrenergic neurotransmission by revealing significant reductions in B/F ratios in the dorsal striatum, in the brain stem and in several cortical areas. Expand
p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson’s Disease
TLDR
The overall findings demonstrate that an adulthood serotoninergic nerve lesion enhanced PCA-evoked DA exocytosis in a rodent model of severe PD, while susceptibility to oxidative stress was unchanged. Expand
Receptors in Striatum of Living Mouse
Aim. To test for a2 adrenergic modulation of dopamine D2/3 receptor availability in striatum of living mice using the high-affinity ligand ( 18 F)fallypride and microPET. Methods. Groups ofExpand
Presynaptic control of serotonin on striatal dopamine function
TLDR
A thorough examination of data showing controversial effects induced by striatal 5-HT on dopaminergic activity suggests that the endogenous 5- HT system exerts multiple and subtle influences on DA-mediated behaviors. Expand
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications
Since their discovery in the mammalian brain, it has been apparent that serotonin (5-HT) and dopamine (DA) interactions play a key role in normal and abnormal behavior. Therefore, disclosure of thisExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum
TLDR
The results show that 5-HT2A and 5- HT2C receptors regulate specifically the activation of midbrain DA neurons induced by amphetamine and morphine, respectively, and suggest that 4-HT1C receptors selectively modulate the impulse flow–dependent release of DA. Expand
Role of Striatal Serotonin2A and Serotonin2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum
TLDR
Results indicate that striatal 5‐HT2A receptors, probably through activation of DA synthesis, positively modulate DA outflow only under activated conditions, which appears to be both tonic and phasic. Expand
Role of Serotonin2A and Serotonin2B/2C Receptor Subtypes in the Control of Accumbal and Striatal Dopamine Release Elicited In Vivo by Dorsal Raphe Nucleus Electrical Stimulation
TLDR
Results indicate that 5‐HT2A but not 5-HT2B/2C receptors participate in the facilitatory control exerted by endogenous 5‐ht on accumbal DA release, and 5‐ HT2B / 2C receptors tonically inhibit basal DA release in both brain regions. Expand
5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.
TLDR
The results suggest a permissive role for 5-HT2 receptors in the activation of the dopamine system which occurs during states of high serotonergic activity or during conditions of elevated dopamine efflux with high D2 receptor occupancy. Expand
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
TLDR
The data indicate that MDL 100,907 has a clozapine-like profile of potential antipsychotic activity with low extrapyramidal sid-effect liability. Expand
Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
TLDR
The 5-HT2 receptor agonist, DOI, dose-dependently increased dialysate levels of dopamine (DA) and noradrenaline (NA) in the frontal cortex (FCX) of freely-moving rats, but not5-HT, in the FCX in vivo, in contrast to a tonic, inhibitory influence of 5- HT2C receptors. Expand
Modulation of dopamine release by striatal 5‐HT2C receptors
TLDR
The results suggest that the nigrostriatal system is regulated by 5‐HT2C receptors localized in the dorsal striatum, and that serotonin (5‐HT) modulates striatal and prefrontocortical DA concentrations may lead to improvements in the treatment of diverse syndromes. Expand
Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors.
TLDR
It is proposed that 5-HT(2A) and alpha1b-adrenergic receptors control a common neural pathway responsible for the release of dopamine in the nucleus accumbens by psychostimulants. Expand
Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study
TLDR
Data indicate that the central serotonergic system exerts a tonic inhibitory control of mesolimbic and nigrostriatal dopaminergic pathway activity and that the serotonin-2C/2B receptor subtypes are involved in this effect. Expand
Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis
  • S. Dewey, G. Smith, +6 authors C. Ashby
  • Chemistry, Medicine
  • The Journal of neuroscience : the official journal of the Society for Neuroscience
  • 1995
TLDR
These data demonstrate that 5- HT-selective drugs produce changes in striatal dopamine that can be measured noninvasively with PET, and have implications for understanding the therapeutic efficacy of atypical neuroleptics and their utility for treating schizophrenia and affective disorders. Expand
...
1
2
3
4
5
...